Status:
COMPLETED
Fibroblast Growth Factor 23 and Sclerostin in Relation to Calcium in COVID-19 Patients
Lead Sponsor:
Aswan University Hospital
Conditions:
COVID-19
Eligibility:
MALE
18+ years
Brief Summary
Hypocalcemia is associated with COVID-19 patients and is linked to poor prognosis, Fibroblast growth factor 23 (FGF23) and Sclerostin inhibit vitamin D activation and are linked to hypocalcemia. Leve...
Detailed Description
COVID 19 is a current worldwide pandemic caused by severe acute respiratory syndrome coronavirus 2 "SARS-CoV-2". Hypovitaminosis D and hypocalcaemia have been reported to be associated with COVID 19 i...
Eligibility Criteria
Inclusion
- Positive COVID 19 (Mild to moderate - severe to critical).
Exclusion
- known diagnosis of CKD.
- Known parathyroid disease.
- Use of phosphate binder therapy within the past 3 months.
- Use of calcium therapy within the past 3 months
- Treatment with 25(OH) vitamin D or 1,25 (OH)(2) D
- Underlying metabolic bone disease.
- Underlying renal phosphate wasting disorder.
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2023
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT05275491
Start Date
May 1 2022
End Date
February 1 2023
Last Update
February 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aswan University hospital
Aswān, Egypt, 81511